
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is developing a promising pipeline of oral immunology therapies for chronic inflammatory and autoimmune diseases, which have a high unmet medical need. The company's lead candidate, IMU-838, has shown impressive results in clinical trials for multiple sclerosis and has the potential to capture significant market share in the relapsing forms of the disease. Additionally, the company's financial position is strong with enough cash to support operations into late 2027, providing potential for long-term growth and success.
Bears say
Immunic is currently developing several potential treatments for chronic inflammatory and autoimmune diseases, but their lead asset, vidofludimus calcium, has shown only modest benefits in clinical trials against RMS, and we anticipate this will limit its market potential among a highly competitive landscape. The company's recent financing, while providing a runway into 2027, may also indicate a lack of confidence in the potential of their pipeline. Additionally, we have concerns about the limited cash reserves prior to the financing, indicating the capital-intensive nature of their late-stage program.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares